These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 28853141)

  • 41. Trimodality therapy and definitive chemoradiotherapy for esophageal cancer: a single-center experience and review of the literature.
    Hategan M; Cook N; Prewett S; Hindmarsh A; Qian W; Gilligan D
    Dis Esophagus; 2015 Oct; 28(7):612-8. PubMed ID: 24863560
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Pathologic nonresponders after neoadjuvant chemoradiation for esophageal cancer demonstrate no survival benefit compared with patients treated with primary esophagectomy.
    Dittrick GW; Weber JM; Shridhar R; Hoffe S; Melis M; Almhanna K; Barthel J; McLoughlin J; Karl RC; Meredith KL
    Ann Surg Oncol; 2012 May; 19(5):1678-84. PubMed ID: 22045465
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Prognosis of esophageal cancer patients with pathologic complete response after preoperative concurrent chemoradiotherapy.
    Park JW; Kim JH; Choi EK; Lee SW; Yoon SM; Song SY; Lee YS; Kim SB; Park SI; Ahn SD
    Int J Radiat Oncol Biol Phys; 2011 Nov; 81(3):691-7. PubMed ID: 20888705
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Long-term outcomes following neoadjuvant chemoradiotherapy in patients with clinical T2N0 esophageal squamous cell carcinoma.
    Chen WH; Chao YK; Chang HK; Tseng CK; Wu YC; Liu YH; Hsieh MJ; Liu HP
    Dis Esophagus; 2012 Apr; 25(3):250-5. PubMed ID: 21951719
    [TBL] [Abstract][Full Text] [Related]  

  • 45. High-dose definitive concomitant chemoradiotherapy in non-metastatic locally advanced esophageal cancer: toxicity and outcome.
    Hurmuzlu M; Monge OR; Smaaland R; Viste A
    Dis Esophagus; 2010 Apr; 23(3):244-52. PubMed ID: 19664075
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Preoperative chemoradiotherapy improves local recurrence free survival in locally advanced rectal cancer.
    Tural D; Ozturk M; Selcukbiricik F; Yildiz O; Elicin O; Turna H; Guney S; Ozguroglu M
    J BUON; 2013; 18(2):385-90. PubMed ID: 23818350
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Definitive chemoradiation for patients with inoperable and/or unresectable esophageal cancer: locoregional recurrence pattern.
    Versteijne E; van Laarhoven HW; van Hooft JE; van Os RM; Geijsen ED; van Berge Henegouwen MI; Hulshof MC
    Dis Esophagus; 2015 Jul; 28(5):453-9. PubMed ID: 24725186
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Twice-daily radiotherapy as concurrent boost technique during two chemotherapy cycles in neoadjuvant chemoradiotherapy for resectable esophageal carcinoma: mature results of phase II study.
    Choi N; Park SD; Lynch T; Wright C; Ancukiewicz M; Wain J; Donahue D; Mathisen D
    Int J Radiat Oncol Biol Phys; 2004 Sep; 60(1):111-22. PubMed ID: 15337546
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Diffusion-weighted magnetic resonance imaging for the prediction of pathologic response to neoadjuvant chemoradiotherapy in esophageal cancer.
    van Rossum PS; van Lier AL; van Vulpen M; Reerink O; Lagendijk JJ; Lin SH; van Hillegersberg R; Ruurda JP; Meijer GJ; Lips IM
    Radiother Oncol; 2015 May; 115(2):163-70. PubMed ID: 26002307
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The usefulness of neoadjuvant chemoradiation therapy for locally advanced esophageal cancer with multiple lymph-node metastases.
    Okumura H; Uchikado Y; Omoto I; Kita Y; Sasaki K; Arigami T; Uenosono Y; Matsushita D; Hiraki Y; Owaki T; Ishigami S; Natsugoe S
    Ann Surg Oncol; 2014 Sep; 21(9):2845-9. PubMed ID: 24728820
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Definitive or Preoperative Chemoradiation Therapy for Esophageal Cancer: Patterns of Care and Survival Outcomes.
    Shao MS; Wong AT; Schwartz D; Weiner JP; Schreiber D
    Ann Thorac Surg; 2016 Jun; 101(6):2148-54. PubMed ID: 27016842
    [TBL] [Abstract][Full Text] [Related]  

  • 52. EMR as salvage treatment for patients with locoregional failure of definitive chemoradiotherapy for esophageal cancer.
    Hattori S; Muto M; Ohtsu A; Boku N; Manabe T; Doi T; Ishikura S; Yoshida S
    Gastrointest Endosc; 2003 Jul; 58(1):65-70. PubMed ID: 12838223
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Impact of docetaxel in addition to cisplatin and fluorouracil as neoadjuvant treatment for resectable stage III or T3 esophageal cancer: a propensity score-matched analysis.
    Nomura M; Oze I; Abe T; Komori A; Narita Y; Masuishi T; Taniguchi H; Kadowaki S; Ura T; Andoh M; Kawai R; Uemura N; Ishihara M; Tanaka T; Tajika M; Niwa Y; Muro K; Muto M
    Cancer Chemother Pharmacol; 2015 Aug; 76(2):357-63. PubMed ID: 26092324
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Can metformin improve 'the tomorrow' of patients treated for oesophageal cancer?
    Van De Voorde L; Janssen L; Larue R; Houben R; Buijsen J; Sosef M; Vanneste B; Schraepen MC; Berbée M; Lambin P
    Eur J Surg Oncol; 2015 Oct; 41(10):1333-9. PubMed ID: 26091848
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Patterns of recurrent disease after neoadjuvant chemoradiotherapy and esophageal cancer surgery with curative intent in a tertiary referral center.
    Schuring N; Stam WT; Plat VD; Kalff MC; Hulshof MCCM; van Laarhoven HWM; Derks S; van der Peet DL; van Berge Henegouwen MI; Daams F; Gisbertz SS
    Eur J Surg Oncol; 2023 Oct; 49(10):106947. PubMed ID: 37355392
    [TBL] [Abstract][Full Text] [Related]  

  • 56. CD44, SHH and SOX2 as novel biomarkers in esophageal cancer patients treated with neoadjuvant chemoradiotherapy.
    Honing J; Pavlov KV; Mul VE; Karrenbeld A; Meijer C; Faiz Z; Smit JK; Hospers GA; Burgerhof JG; Kruyt FA; Kleibeuker JH; Plukker JT
    Radiother Oncol; 2015 Oct; 117(1):152-8. PubMed ID: 26364884
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Ineffectiveness of ¹⁸F-fluorodeoxyglucose positron emission tomography in the evaluation of tumor response after completion of neoadjuvant chemoradiation in esophageal cancer.
    Piessen G; Petyt G; Duhamel A; Mirabel X; Huglo D; Mariette C
    Ann Surg; 2013 Jul; 258(1):66-76. PubMed ID: 23470576
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Association Between Clinically Staged Node-Negative Esophageal Adenocarcinoma and Overall Survival Benefit From Neoadjuvant Chemoradiation.
    Gabriel E; Attwood K; Du W; Tuttle R; Alnaji RM; Nurkin S; Malhotra U; Hochwald SN; Kukar M
    JAMA Surg; 2016 Mar; 151(3):234-45. PubMed ID: 26559488
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Stage for stage comparison of recurrence patterns after definitive chemoradiotherapy or surgery for oesophageal carcinoma.
    Reid TD; Davies IL; Mason J; Roberts SA; Crosby TD; Lewis WG
    Clin Oncol (R Coll Radiol); 2012 Nov; 24(9):617-24. PubMed ID: 22386923
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Patterns of recurrence in patients achieving pathologic complete response after neoadjuvant chemoradiotherapy for rectal cancer.
    Fan WH; Xiao J; An X; Jiang W; Li LR; Gao YH; Chen G; Kong LH; Lin JZ; Wang JP; Pan ZZ; Ding PR
    J Cancer Res Clin Oncol; 2017 Aug; 143(8):1461-1467. PubMed ID: 28386648
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.